An Advanced Blood Test proves to be beneficial for Rheumatoid Arthritis

Primary tabs

NEWS
An Advanced Blood Test proves to be beneficial for Rheumatoid Arthritis

According a report was published online in the journal Arthritis & Rheumatology, an advanced blood test predict treatment response in patients suffering from rheumatoid arthritis (RA). 

As per Elena Hitraya, M.D., Ph.D., Chief Medical Officer, Crescendo Bioscience, "This study highlights the clinical utility of the test to help predict treatment response to biologic and non-biologic therapies in methotrexate incomplete responders. These results showed that this blood test performed better than clinical and single inflammatory biomarkers at predicting response to non-biological therapy intensification versus anti-TNF (infliximab) therapy. This publication adds to the growing of data on the use of the test to help individualize treatment plans and improve health outcomes for patients with RA”.

The study was performed to evaluate whether the test score could be used to predict the optimal choice of second-line treatment for 157 patients with RA who were methotrexate incomplete responders (MTX-IR). The study depicted that in patients with early RA and incomplete response to MTX, the test estimated those who were more likely to respond to the treatment with triple therapy versus anti-TNF. Particularly, patients with a lower blood test score at three months following MTX monotherapy treatment were more likely to respond to triple therapy versus MTX+infliximab (88% vs. 18%, respectively; p=0.006). In contrast, at three months, patients who had a high blood test score were more likely to respond to anti-TNF therapy (35% vs. 58% respectively; p=0.040). Significantly, the blood test score at three months was a better independent predictor of treatment response at Year 1 than the clinical or single inflammatory biomarkers (CRP, ESR) or DAS28). These results reveal that Vectra DA could be used to direct biologic or non-biologic treatment decisions in  RA patients at early stage who do not respond to MTX monotherapy in the first three months.

The first and only multi-biomarker blood test validated to determine DA in patients with RA is this blood test. In more than 20 studies with more than 3,000 patients, this test has been used. In US, the value this advanced test offers rheumatologists are demonstrated by the fact that 3 out of 4 rheumatologists have ordered Vectra DA for ~300,000 patients.

Lately, this blood test was included in guidelines published by United Rheumatology, and will be assessed for inclusion in the American College of Rheumatology (ACR) guidelines.

Source:

Globe NewsWire

Link to the source:

https://www.einpresswire.com/article/359576354/positive-clinical-utility-results-of-crescendo-s-vectra-da-test-for-rheumatoid-arthritis-published-in-the-journal-arthritis-rheumatology

Original title of article:

Positive Clinical Utility Results of Crescendo’s Vectra® DA Test for Rheumatoid Arthritis Published in the Journal Arthritis & Rheumatology

Globe NewsWire
Log in or register to post comments